Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates (ADCs) in B-cell malignancies.

Polatuzumab vedotin, an ADC, is being studied in combination with rituximab (Rituxan) or obinutuzumab (Gazyva) in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).

As for ADCs in this space, there has been success with brentuximab vedotin, which is approved by the FDA in classical Hodgkin lymphoma.